EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

[Image: see text] Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ACS Med Chem Lett
Autori principali: Campbell, John E., Kuntz, Kevin W., Knutson, Sarah K., Warholic, Natalie M., Keilhack, Heike, Wigle, Tim J., Raimondi, Alejandra, Klaus, Christine R., Rioux, Nathalie, Yokoi, Akira, Kawano, Satoshi, Minoshima, Yukinori, Choi, Hyeong-Wook, Porter Scott, Margaret, Waters, Nigel J., Smith, Jesse J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Chemical Society 2015
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434464/
https://ncbi.nlm.nih.gov/pubmed/26005520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00037
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi